Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 64Neoplasms 37Colorectal Neoplasms 35Neoplasm Metastasis 32Breast Neoplasms 31Ovarian Neoplasms 28Prostatic Neoplasms 27Pancreatic Neoplasms 27Recurrence 26Multiple Myeloma 25Melanoma 24Squamous Cell Carcinoma of Head and Neck 23Glioblastoma 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lung Neoplasms 18Endometrial Neoplasms 18Triple Negative Breast Neoplasms 17Lymphoma, Large B-Cell, Diffuse 16Lymphoma, Non-Hodgkin 15Stomach Neoplasms 14Leukemia, Myeloid, Acute 14Colonic Neoplasms 14Burkitt Lymphoma 14Carcinoma, Renal Cell 13Small Cell Lung Carcinoma 12Glioma 12Uterine Cervical Neoplasms 11Sarcoma 11Lymphoma 11Head and Neck Neoplasms 11

Interventions

Taxes 1Gemcitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Metastatic Pancreatic Ductal Adenocarcinoma × 30 days × Clear all
NCT06904378 2026-05-19

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

Phase 1/2 Recruiting
61 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡